- Recent IPO Vitae Pharmaceuticals (NASDAQ:VTAE) is up 33% premarket on higher-than-normal volume in response to its announcement of results from a Phase 1 trial of its BACE inhibitor, VTP-37948, in Alzheimer's patients. The drug candidate appeared safe and tolerable. Partner Boehringer Ingelheim expects to initiate more Phase 1 studies to clarify the pharmacokinetic profile and ascending dose characteristics.